Medifast Announces First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Medifast (MED) stock plunges on earnings miss, weak outlook
April 30, 2024 9:08 AM EDTMedifast (NYSE: MED), a wellness company known for its OPTAVIA brand, reported a significant decline in first-quarter revenue and earnings after the close on Monday, missing Wall Street estimates and projecting weaker-than-expected guidance for the second quarter. The company's shares plummeted 25% as investors reacted to the disappointing results and outlook.
For the first quarter ended March 31, 2024, Medifast's revenue fell to $174.7 million, a sharp 49.9% decrease from $349.0 million in the same quarter last year. This decline significantly missed the analyst consensus of $205.79 million. The company's adjusted earnings per share (EPS) for the quarter was $0.66,... More
Medifast (MED) PT Lowered to $25 at DA Davidson
April 30, 2024 5:00 AM EDTDA Davidson analyst Linda Bolton Weiser lowered the price target on Medifast (NYSE: MED) to $25.00 (from $40.00) while maintaining a Neutral rating.
The analyst comments "NEUTRAL-rated MED reported a small 1Q24 sales beat but profit missed consensus by 11% due to higher SG&A... More
Medifast (MED) Misses Q1 EPS by 84c, Guidance Misses
April 29, 2024 4:10 PM EDTMedifast (NYSE: MED) reported Q1 EPS of $0.66, $0.84 worse than the analyst estimate of $1.50. Revenue for the quarter came in at $174.7 million versus the consensus estimate of $205.79 million.
GUIDANCE:
Medifast sees Q2 2024 EPS of $0.05-$0.40, versus the consensus of $0.67. Medifast sees Q2... More
